Cargando…

Efficacy of Glecaprevir/Pibrentasvir for Real-World HCV Infected Patients in the Northern Part of Tokyo, Japan

Hepatis virus C (HCV) infection causes liver cirrhosis and hepatocellular carcinoma (HCC) worldwide. The objective of our study was to examine the effects of the HCV nonstructural protein (NS) 3/4A inhibitor glecaprevir/NS5A inhibitor pibrentasvir on real-world HCV patients in the northern part of T...

Descripción completa

Detalles Bibliográficos
Autores principales:	Yamana, Yoichiro, Kanda, Tatsuo, Matsumoto, Naoki, Honda, Masayuki, Kumagawa, Mariko, Sasaki, Reina, Kanezawa, Shini, Mizutani, Taku, Yamagami, Hiroaki, Masuzaki, Ryota, Ishii, Tomotaka, Nirei, Kazushige, Moriyama, Mitsuhiko
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8658140/ https://www.ncbi.nlm.nih.gov/pubmed/34884231 http://dx.doi.org/10.3390/jcm10235529

Ejemplares similares

Japanese Man with HCV Genotype 4 Infection and Cirrhosis Who Was Successfully Treated by the Combination of Glecaprevir and Pibrentasvir
por: Totsuka, Mai, et al.
Publicado: (2021)

Male-Dominant Hepatitis A Outbreak Observed among Non-HIV-Infected Persons in the Northern Part of Tokyo, Japan
por: Honda, Masayuki, et al.
Publicado: (2021)

Occurrence of hepatitis in an elderly woman during the treatment of pembrolizumab for right advanced renal pelvis, ureteral cancer, and bladder cancer
por: Asatani, Shinya, et al.
Publicado: (2021)

Portal-systemic Encephalopathy due to Complicated Spleno-renal Shunt Successfully Treated with Balloon-occluded Retrograde Transvenous Obliteration Using a Double Coaxial Balloon Catheter System and Shape-memory Coils
por: Matsuoka, Shunichi, et al.
Publicado: (2018)

Follow-Up of Patients Who Achieved Sustained Virologic Response after Interferon-Free Treatment against Hepatitis C Virus: Focus on Older Patients
por: Nirei, Kazushige, et al.
Publicado: (2021)

Muscle Cramps in Outpatients with Liver Diseases in Tokyo, Japan
por: Kanda, Tatsuo, et al.
Publicado: (2023)

Left Gastric Vein Width Is an Important Risk Factor for Exacerbation of Esophageal Varices Post Balloon-Occluded Retrograde Transvenous Obliteration for Gastric Varices in Cirrhotic Patients
por: Mizutani, Taku, et al.
Publicado: (2022)

Co-Occurrence of Hepatitis A Infection and Chronic Liver Disease
por: Kanda, Tatsuo, et al.
Publicado: (2020)

Nationwide registry of glecaprevir plus pibrentasvir in the treatment of HCV in Taiwan
por: Huang, Chung-Feng, et al.
Publicado: (2021)

Efficacy and Safety of Glecaprevir/Pibrentasvir in Patients with Chronic HCV Infection
por: Liu, Xiaoqing, et al.
Publicado: (2021)

Ventricular Tachycardia as a Complication of Ledipasvir and Sofosbuvir Treatment for HCV Infection
por: Nirei, Kazushige, et al.
Publicado: (2017)

Gut-Microbiota Dysbiosis in Stroke-Prone Spontaneously Hypertensive Rats with Diet-Induced Steatohepatitis
por: Kanezawa, Shini, et al.
Publicado: (2023)

Efficacy and safety of glecaprevir/pibrentasvir in patients with chronic HCV infection and psychiatric disorders: An integrated analysis
por: Back, David, et al.
Publicado: (2019)

Pharmacokinetics, Safety, and Efficacy of Glecaprevir/Pibrentasvir in Children With Chronic HCV: Part 2 of the DORA Study
por: Jonas, Maureen M., et al.
Publicado: (2021)

Persistent Hepatic Inflammation Plays a Role in Hepatocellular Carcinoma After Sustained Virological Response in Patients with HCV Infection
por: Nirei, Kazushige, et al.
Publicado: (2018)

Glecaprevir/Pibrentasvir in patients with chronic HCV genotype 3 infection: An integrated phase 2/3 analysis
por: Flamm, Steven, et al.
Publicado: (2018)

Glecaprevir-pibrentasvir for 4 weeks among people with recent HCV infection: The TARGET3D study
por: Martinello, Marianne, et al.
Publicado: (2023)

Real-World Effectiveness of 8-Week Glecaprevir/Pibrentasvir in Treatment-Naïve, Compensated Cirrhotic HCV Patients
por: Reau, Nancy, et al.
Publicado: (2023)

Suppressors of Cytokine Signaling and Hepatocellular Carcinoma
por: Masuzaki, Ryota, et al.
Publicado: (2022)

Adherence to pan‐genotypic glecaprevir/pibrentasvir and efficacy in HCV‐infected patients: A pooled analysis of clinical trials
por: Brown, Ashley, et al.
Publicado: (2019)

Safety and effectiveness of 8 weeks of Glecaprevir/Pibrentasvir in challenging HCV patients: Italian data from the CREST study
por: Aghemo, Alessio, et al.
Publicado: (2023)

Efficacy and safety of glecaprevir/pibrentasvir in patients with HCV genotype 5/6: An integrated analysis of phase 2/3 studies
por: Yao, Betty B., et al.
Publicado: (2020)

Efficacy and Safety of Glecaprevir/Pibrentasvir in HCV Patients With Previous Direct-Acting Antiviral Therapy Failures: A Meta-Analysis
por: Shen, Chao, et al.
Publicado: (2020)

Retreatment of patients with treatment failure of direct-acting antivirals: Focus on hepatitis C virus genotype 1b
por: Kanda, Tatsuo, et al.
Publicado: (2017)

Addressing HCV Elimination Barriers in Italy: Healthcare Resource Utilization and Cost Impact Using 8 Weeks’ Glecaprevir/Pibrentasvir Therapy
por: Andreoni, Massimo, et al.
Publicado: (2021)

Safety and Effectiveness Using 8 Weeks of Glecaprevir/Pibrentasvir in HCV-Infected Treatment-Naïve Patients with Compensated Cirrhosis: The CREST Study
por: Cornberg, Markus, et al.
Publicado: (2022)

Glecaprevir/pibrentasvir for the treatment of chronic hepatitis C: design, development, and place in therapy
por: Cotter, Thomas G, et al.
Publicado: (2019)

Risk Factors of Glecaprevir/Pibrentasvir-Induced Liver Injury and Efficacy of Ursodeoxycholic Acid
por: Tamai, Hideyuki, et al.
Publicado: (2023)

Effectiveness and safety of 8-week glecaprevir/pibrentasvir in HCV treatment-naïve patients with compensated cirrhosis: real-world experience from Taiwan nationwide HCV registry
por: Chang, Te-Sheng, et al.
Publicado: (2023)

Efficacy and safety of glecaprevir/pibrentasvir in HCV-infected Japanese patients with prior DAA experience, severe renal impairment, or genotype 3 infection
por: Kumada, Hiromitsu, et al.
Publicado: (2017)

The Successful Retreatment with Glecaprevir and Pibrentasvir of Genotype 1 or 2 HCV-infected Hemodialysis Patients who Failed to Respond to NS5A and Protease Inhibitor Treatment
por: Suda, Goki, et al.
Publicado: (2018)

Glecaprevir/Pibrentasvir Treatment in Liver or Kidney Transplant Patients With Hepatitis C Virus Infection
por: Reau, Nancy, et al.
Publicado: (2018)

Four Weeks Treatment with Glecaprevir/Pibrentasvir + Ribavirin—A Randomized Controlled Clinical Trial
por: Madsen, Lone W., et al.
Publicado: (2022)

Efficacy and Safety of 8- or 12 Weeks of Glecaprevir/Pibrentasvir in Patients with Evidence of Portal Hypertension
por: Brown, Robert S., et al.
Publicado: (2022)

Glecaprevir/pibrentasvir + sofosbuvir for post-liver transplant recurrent hepatitis C virus treatment
por: Arora, Rishi, et al.
Publicado: (2023)

Severe Psoriasis Successfully Treated with Brodalumab after Eradication of Hepatitis C Virus with Glecaprevir and Pibrentasvir: A Case Report
por: Ito, Michiko, et al.
Publicado: (2021)

Correction to: Efficacy and safety of glecaprevir/pibrentasvir in HCV-infected Japanese patients with prior DAA experience, severe renal impairment, or genotype 3 infection
por: Kumada, Hiromitsu, et al.
Publicado: (2017)

Chronic Hepatitis C: Acute Exacerbation and Alanine Aminotransferase Flare
por: Kanda, Tatsuo, et al.
Publicado: (2023)

Use of glecaprevir/pibrentasvir in patients with chronic hepatitis C virus infection and severe renal impairment
por: Yap, Desmond Y. H., et al.
Publicado: (2020)

Effectiveness of Glecaprevir/Pibrentasvir for Hepatitis C: Real-World Experience and Clinical Features of Retreatment Cases
por: Sugiura, Ayumi, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_2vmhnpm0kjcdugr4utfb5ega11